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     The addition of the Bone Morphogenetic Proteins 
to the plethora of cytokines that affect the paracrine 
control of ovarian follicle development, although 
recent has been very fruitful to understand the 
physiology of the mammalian ovary. They proved 
to be involved key steps since the very beginning 
during the formation of the foetal ovary, passing to 
the entry of        primordial follicles into the growing pool, 
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granulosa and theca cell function and finally affecting the number of follicles 
capable of ovulating. The mammalian domestic species offer an excellent 
comparison to the rodent models used to investigate folliculogenesis. The 
sheep naturally occurring mutations in Bone Morphogenetic Proteins ligands 
and receptor are particularly interesting and have shed some light on very 
fundamental steps of folliculogenesis and on the regulation of ovulation rate. 
 
Introduction 
 The Bone Morphogenetic Proteins (BMPs) are members of the 
Transforming Growth Factor beta (TGFbeta) family of growth factors and are 
deeply involved in the growth and differentiation of several cell lines including 
those of the female reproductive system and particularly the ovary [1]. 
 The existence of several major genes (mutations) affecting ovulation rate 
in sheep has been known for more than 25 years [2] and some of them have 
been used extensively as models to understand the folliculogenesis in 
mammals [3, 4]. The genetic cause of some of these major genes were point 
mutations on BMP-15 and BMP receptor type 1 B (BMPRIB) genes, which 
brought the attention to the BMPs as regulators of ovarian follicle development 
and ultimately the ovulation rate in domestic species [5-8]. There are several 
recent reviews on the effect of members of the TGFbeta on folliculogenesis [9-
11]. This review will focus on the effects of BMPs in the control of ovarian 
follicular growth in domestic animals but we will borrow information from 
rodent models whenever it becomes necessary. 
 
BMPs signalling system 
 The BMPs comprises the largest family among the TGFbeta superfamily 
of growth factors. They are products of single genes that are translated as large 
preproteins composed of a signal peptide, predomain, and mature domain. 
After removal of the signal peptide, the proproteins undergo dimerization and 
are cleaved at a specific site (RXXR) by proteolytic enzymes, generating 
biologically active dimers of the mature protein. Recombinant protein 
expression systems revealed that when coexpressed, BMP-2, -4, -5, -6, and -7 
can form heterodimers which often exhibit greater biological activity than their 
corresponding homodimers (for review see [9, 12]). There is also evidence that 
both BMP-15 and GDF-9 form non-covalent homodimers when expressed 
individually, while BMP-15/GDF-9 heterodimers are produced when both are 
co-expressed. When GDF-9 and BMP-15 are co-expressed the processing of 
both proproteins are reduced compared to that of individually expressed 
proproteins, suggesting that the proprotein heterodimer is less susceptible to 
proteolytic cleavage than the individual homodimers [13]. 
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Table 1. Principal BMP ligands identified in the mammalian ovary, their preferred 
receptors and intracellular signalling pathway. 
 
 
 Ligand Type II receptor Type I receptor Smad 
BMP-2 
BMP-4 









ActR1A (ALK 2) / 
BMPRIB (ALK6) 
Smad1/5/8 
BMP-15 BMPRII BMPRIB (ALK6) Smad1/5/8 
GDF-9 BMPRII TGFbetaR1 (ALK5) Sma2/3     
  
           Adapted from [9] after [16] 
 
 The Table 1 summarises the ligands, receptors and signalling pathway of 
the BMPs most commonly present in the mammalian ovary. This family of 
peptides signals through a complex of single transmembrane domain receptors 
comprising of serine-threonine kinase receptors type I and II (Table 1). Upon 
ligation with the high affinity receptors, dimeric BMPs recruit the other 
receptors to form a heterotetrameric complex. The constitutively phosphorylated 
type II receptor transphosphorylate the type I receptor leading to the activation 
of their intracellular kinases. Once activated, the BMP type 1 receptor 
phosphorylates a receptor-regulated Smad (Smad 1, 5 or 8) which then 
heterodimerizes with a common Smad (Smad-4) and moves to the nucleus 
where the Smad complex associates with nuclear transcription factors and 
regulate the expression of target genes (for review see [14, 15]). 
 
BMPs and the formation of the ovary in the foetus 
 The effect of BMPs on the folliculogenesis is first evidenced in the 
formation and early proliferation of the primordial germ cells (PGCs) in the 
foetus in utero. Mouse embryos homozygous null for BMP-4 contain no PGCs 
and also lack other extraembryonic mesoderm derived tissue such as the 
allantois, which along with the PGCs originate from the proximal epiblast. 
BMP- 4 null heterozygotes have fewer PGCs, due to a reduction in the size of 
the founding population [17]. 
 Mouse embryos with BMP-8b gene knockout also have a reduction in the 
PGC numbers and the severity of the decrease varies according with the 
number of defective alleles and the genetic background of the mutants [18]. 
However, the effects of BMP-4 and BMP-8b on mouse PGC are not additive 
[18]. In epiblast cultures BMP-4 or BMP-8b alone cannot induce PGCs in vitro 
whereas they can when used in combination. Moreover, the PGC defects of 
BMP-8b mutants can be rescued by BMP-8b homodimers while BMP-4 
homodimers cannot mitigate the PGC defects of BMP-4 null mutants, 
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suggesting that BMP-4 proteins are also required prior the synergistic action of 
BMP-4 and BMP-8b [19]. 
 BMP-2 is expressed in the visceral endoderm at the time of PGC 
specification, and inactivation of BMP-2 results in a reduction in PGC number 
[20]. BMP-4 produced in the extraembryonic ectoderm signals through ALK2 
expressed in the visceral endoderm to induce formation of PGCs from the 
epiblast. ALK2-deficient embryos are devoid of PGCs and the heterozygotes 
have reduced numbers, resembling BMP-4 null mutants [21]. 
 Addition of BMP-4 to an in vitro organ culture induced formation and 
migration of PGC to the developing gonad, which was abolished by the addition 
of the BMP-antagonist noggin. Endogenous BMPs induced phosphorylation of 
Smad1/5/8 in the somatic cells of the urogenital ridges but not on migratory 
PGCs. suggesting that BMP signalling regulates PGC migration by controlling 
gene expression within the somatic cells along the migration route and within 
the genital ridges [22]. 
 The expression of BMPs during foetal ovarian development at ages 
ranging from 25 to 120 days post coitum (dpc) has been studied in sheep by 
RT-PCR. Expression of GDF-9 mRNA started at 56 dpc and progressively 
increased reaching a maximum at 94 dpc and then decreasing at birth. BMP-15 
showed a more restricted expression pattern, with high transcription from 94 
dpc to birth. The pattern of BMPRIB expression was high from 56 dpc and 
remained high at all foetal stages [23]. Transcripts of BMP-4, BMPRII and 
BMPRIA were also detected in the sheep foetal ovary since 32 dpc [24]. 
 The consistently high expression of BMPRIB in the foetus is consistent 
with an important role for this receptor in ovarian development. The growth of 
ovaries of foetuses carrying the Booroola mutation is retarded with lower germ 
cell numbers from 30 to 40 dpc, fewer oogonia entering meiosis at day 55, 
fewer developing primordial follicles at 75 and 90 dpc and growing follicles 
from 120 dpc [25]. However, the possible differences among the Booroola 
genotypes on the pattern of gene expression during the ovarian development 
have not been investigated.  
 Expression of BMP-4, -5, and 6 and GDF-9 mRNAs was also observed in 
the ovaries of neonatal pigs [26]. 
 
Ovarian BMP receptors  
 Receptors for BMPs are expressed at all stages of ovarian development. 
The expression of BMPRIA, BMPRIB and BMPRII investigated by 
immunohistochemistry in the sheep ovary showed strong immunostaining in 
the granulosa cell layer of follicles from the primary to late antral stages of 
development. Immunostaining for all three receptors was also present in the 
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oocyte, corpus luteum, ovarian surface epithelium and, to a lesser extent, the 
theca layer of antral follicles [27]. 
 Bovine isolated theca, granulosa and oocytes studied by immuno-
cytochemistry also expressed a range of BMP-responsive type-I (BMPRIB, 
ActRI) and type-II (BMPRII, ActRII, ActRIIB) receptors that after stimulation 
by BMP-4, 6 and 7 promoted cellular accumulation of phosphorylated Smad1 
but not Smad2 [28]. 
 Immunohistochemistry for BMPRIA, BMPRIB and BMPRII in pig 
ovaries demonstrated the presence of all three receptors in the foetal egg nests 
and in the granulosa cell layer of follicles ranging from primordial to late 
antral stages. Immunostaining was also observed in oocytes, theca layer, 
corpus luteum and ovarian surface epithelium [29]. 
 The mRNAs of BMPRII, BMPRIA, and BMPRIB were also detected in 
the ovary of cycling goats by RT-PCR. Transcripts for all BMP receptors were 
detected in primordial, primary, and secondary follicles as well as in oocyte 
and granulosa cells of antral follicles and in the corpora lutea [30]. 
 
Ovarian BMP expression  
 Ovine and bovine ovaries express GDF-9 mRNA in the oocyte of follicles 
from the primordial stage onwards, in a pattern consistent with a role in the 
initiation and maintenance of folliculogenesis in these species [31]. The sheep 
ovary also expresses BMP-15 with transcripts being detected in primary 
follicles after the granulosa cells have undergone two doublings [5]. 
 BMP expression in the sheep ovary investigated by northern blot of 
ovarian tissues comprising large and small antral follicles, isolated granulosa 
and theca cells from large antral follicles showed that BMP-4 and -7 are highly 
expressed in all tissues investigated. BMP-2 is expressed on granulosa cells at 
a lesser intensity but nevertheless present in the sheep ovary, and BMP-6 is 
expressed in the oocyte since RNA expression was observed in intact follicles 
but not in granulosa or theca cells [3]. The expression of BMP-6 in the sheep 
ovary was also observed by immunohistochemistry in the oocyte, granulosa, 
and thecal layers of antral follicles [32]. A recent study using in situ 
hybridization confirmed the BMP- 6 expression restricted to sheep oocytes but 
did not detected BMP-2, 4 and 7 in any cells of non-atretic ovarian follicles. 
However, expression of all BMPs was evident by RT-PCR using RNA from 
isolated granulosa cells [33]. 
 In the cattle ovary, immunohistochemistry revealed expression of BMP-4 
and 7 in isolated theca cells while BMP-6 was expressed selectively in granulosa 
cells and oocytes [28]. Another study corroborated the protein expression 
pattern of BMP-4 and found that expression by immunohistochemistry of 
BMP-2 was limited to theca interna and approximately 25% of oocytes of 
antral follicles [34].  However the same study found that BMP-4 mRNA 
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expression by PCR was present also in the granulosa layer and oocytes of 
antral follicles but BMP-2 mRNA expression remained confined to the theca 
cells [34]. 
 Investigation of BMPs in pig ovaries by Western blotting, showed that 
oocytes and follicular fluid contained BMP- 2 which was also observed in 
granulosa and theca cells. BMP-6 protein was evident on oocytes, follicular 
fluid and in granulosa cells but lacking in theca cells [35]. The pig ovary also 
shows expression of BMP-4, -5, -6, -15 and GDF-9 mRNAs [26, 36]. 
 Investigation of mRNA expression of GDF-9, BMP-15 in the goat ovary 
using RT-PCR detected transcripts of both genes in primordial, primary, and 
secondary follicles as well as in oocyte and granulosa cells of antral follicles. 
GDF-9 and BMP-15 protein localization investigated by immunohistochemistry 
were observed in oocytes of all types of follicles and granulosa cells of primary, 
secondary, and antral but not primordial follicles [30]. 
 
BMPs action on granulosa cells 
 BMP-4 reduces progesterone secretion by ovine granulosa cells cultured  
in vitro [6, 37]. This inhibitory action was associated with a decrease at mRNA 
and protein levels of steroidogenic acute regulatory protein (StAR) and P450 
side-chain cleavage (P450scc) [38]. Addition of BMP-2, -4, -6 or -7 inhibited 
progesterone production from cultured ovine granulosa cells without affecting 
cellular proliferation [33]. Another study using BMP-2, -4, -6, -15 or GDF-9 
also reported reduction of progesterone secretion by sheep granulosa cells in 
culture and no effect on cell proliferation by any of the tested growth factors 
apart from BMP-4 [24]. However the physiological significance of these 
findings is unknown because the follicle mainly secretes oestradiol rather than 
progesterone prior to luteinization.  The unequivocal marker of granulosa cell 
differentiation is its ability to secrete oestradiol. Culture of sheep granulosa 
cells differentiated in vitro in a serum-free medium, showed that BMP-2 
enhanced oestradiol and inhibin-A production but had no effect on cell 
proliferation [27].  A recent study using the same culture system that maintain 
granulosa cell phenotype confirmed the action of BMP-2 and showed that 
BMP-4 and -6 also stimulated oestradiol without causing any change on cell 
number [32]. 
 Experiments with bovine granulosa cells cultured under the same 
conditions as ovine, demonstrated that BMP-4, -6 and -7 enhanced secretion of 
oestradiol, inhibin-A, activin-A and follistatin and increased viable cell 
number but suppressed progesterone secretion, consistent with an action to 
prevent or delay atresia and/or luteinization [28].  Granulosa cells obtained 
from cattle large follicles, treated with GDF-9 showed a dose-dependent 
decrease in progesterone and oestradiol production, but promoted granulosa 
cell proliferation. In the same culture system, treatment with BMP-4 also 
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inhibited steroidogenesis but had no effect on cell numbers [39]. Suggesting 
that the action of BMPs in the cow granulosa cells can be altered by the culture 
system employed. 
 Porcine granulosa cells cultured in a serum-free system with increasing 
concentrations (0 to 100 ng/ml) of BMP-2 or BMP-6, showed that both BMPs 
suppressed progesterone production in a dose-dependent manner, but had no 
effect on cell proliferation apart from BMP-6 at the highest dose. BMP-2 and -
6 decreased cyclic adenosine monophosphate (cAMP) and protein expression 
of 3beta-hydroxy- steroid dehydrogenase (3beta-HSD), while StAR expression 
was only affected by BMP-6 treatment. Supporting the hypothesis that BMP-2 
and -6 act as luteinization inhibitors in the pig granulosa [35]. 
 
BMPs action on theca cells 
 The effects of BMPs on theca cell function are variable depending on dose, 
culture system and species. In cultured bovine theca cells BMP-4, -6, and -7 
suppressed both basal and LH-induced androgen production while had only a 
moderate effect on progesterone production and cell number [40]. 
Semiquantitative RT-PCR showed that all three BMPs induced a marked 
reduction of mRNA for P450 17alpha-hydroxylase (P450c17). While abundance 
of mRNA encoding StAR, P450ssc and 3beta-HSD were also reduced but to a 
much lesser extent. The marked reduction in cellular content of P450c17 protein 
after BMP treatment was confirmed by immunocytochemistry. Treatment of 
bovine theca cells with BMPs led to accumulation of phosphorylated Smad1, but 
not Smad2, confirming the signalling through the Smad1 pathway [40].These 
findings suggest that in this species BMPs suppress androgen production by 
theca cells due direct inhibition of P450c17.  
 In the pig BMP-2 and -6 also suppress progesterone and androstenedione 
synthesis by cultured theca cells. Oestradiol synthesis is suppressed by BMP-2, 
but not BMP-6, and theca cell proliferation is stimulated by BMP-6, while 
BMP-2 show no action. Both BMP-6 and -2 inhibited cAMP release theca 
cells. Addition of BMP-2 and 6 to co-cultured theca and granulosa cells 
suppresses progesterone and androstenedione synthesis while stimulating cell 
proliferation [41].   
 The effect of BMP-2, -4, and -6 was also examined in sheep theca cells in 
culture. High doses of BMPs inhibited LH-stimulated androstenedione 
production, whereas lower doses stimulated cellular proliferation [32]. 
 In summary these observations suggest that BMPs may stimulate aromatase 
activity in granulosa cells but inhibit androgen production by theca cells. In this 
way premature luteinization of the developing follicle is prevented. 
BMPs antagonists 
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 The effect of BMPs can also be regulated in the extracellular milieu by 
antagonists such as noggin, follistatin, chordin and cerberus, which bind to 
ligands with high affinity interfering in receptor coupling. The action of BMPs 
is also regulated at the membrane site by pseudo receptors like BAMBI and 
soluble forms of type I receptors (for review see [42]). 
 A bioassay based on progesterone production by ovine granulosa cells in 
culture, showed that follistatin was a strong antagonist of activin A, but not 
BMP-2 or BMP-4 actions. In contrast, noggin, a known specific BMP 
antagonist, had no effect on activin-A but strongly neutralized BMP-2 and 
BMP-4 actions. Both follistatin and noggin showed a lesser reduction on BMP-
6 action [43]. The relative binding affinity of follistatin for BMP-4, -6 and -7 
were 10, 5 and 1% respectively when compared to activin [28]. Moreover, 
studies on bovine granulosa cells showed that preincubation of BMP-4, -6 or -
7 with excess follistatin abolished BMP-4-induced phosphorylation of Smad-1, 
partially reversed Smad-1 phosphorylation induced by BMP-6 while it had no 
inhibitory effect on BMP-7-induced Smad-1 phosphorylation [28]. 
 Bovine theca cultures treated with BMP-4, -6, and -7 and coincubated with 
BMP antagonists, chordin, gremlin, and follistatin, demonstrated that gremlin 
and chordin were effective antagonists of BMP-4 and -7 induced suppression 
of androstenedione (A4) secretion but had no effect on BMP-6 action.  
Follistatin failed to reverse the effects of BMPs on androgen production [40]. 
 
BMP effects on cumulus expansion  
 Recent data has suggested that BMPs may be important regulators of the 
dialogue between the oocyte and its surrounding cumulus granulosa cells. 
When the oocyte is removed from the cow follicle cultured in vitro the 
surrounding granulosa cells undergo apoptosis which can be prevented by the 
addition of  BMP-15 [44]. In the same work effects of other BMPs were much 
less (BMP-6) or absent (GDF-9). 
 In contrast several studies in the mouse and rat suggest that GDF-9 may 
play a crucial role in cumulus expansion. When GDF-9 antisense RNA was 
microinjected into cultured rat follicles, there was a striking increase of GC 
apoptosis and inhibition of follicle growth [45]. A study demonstrated the 
induction of cumulus expansion of oocytectomized mouse COCs in presence 
of GDF-9, FSH and foetal calf serum (FCS), setting the GDF-9 as candidate to 
be the cumulus-expansion enabling factor (CEEF) [46].  More recently, two 
other studies provided additional evidence that  GDF-9 may be the elusive 
CEEF. The first one, using a RNA interference strategy to knockdown the 
expression of GDF-9 and BMP-15 proteins in mouse oocytes microinjected 
with dsRNAs, showed that GDF-9 knockdown oocytes, but not BMP-15, were 
unable to induce cumulus expansion in oocytectomized mouse COCs in 
presence of FSH [47]. A distinct result was obtained in the second study 
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employing GDF-9, TGFbeta, and their respective antagonists, mAb-GDF-9 
(monoclonal anti-human GDF-9) and TGFbRII ECD (extra cellular domain of 
TGFbeta type II receptor). This work showed that neither GDF-9 nor TGFbeta 
alone could account for the oocyte-secreted factors with CEEF proprieties 
[48]. However, the evidence that the CEEF is composed by molecules of the 
TGFbeta superfamily is further confirmed by the fact that disruption of SMAD 
2/3 signalling completely ablated the initiation of mouse cumulus expansion 
[49]. 
 In summary these studies support the concept that BMPs including oocyte 
derived factors such as GDF-9 and BMP15 play an important part in regulating 
the activity of the somatic (granulosa) cell component of the follicle. Whether 
the contrasting studies with different ligands are due to species differences or 
in the test system used is unknown.  
 
BMPs and ovulation rate 
 A number of strains of sheep have been observed which have a lambing 
and ovulation rate well above that observed in the parent breed (usually 1-2). It 
has now been shown to be associated with single point mutations in genes of 
the BMPs or their receptors (Table 2). 
 The first naturally occurring mutations (Table 2) in a BMP ligand was 
identified in Romney ewes selected for their increased ovulation rate [5]. 
Heterozygous ewes of the Hanna and Inverdale point mutations on the     
BMP-15 gene have an extra ovulation above wild type, while homozygous 
ewes are infertile and have streak ovaries devoid of follicles with more than 
one layer of granulosa cells [50]. The BMP-15 gene has proved to be a 
mutation “hot spot” in prolific sheep with identification of the Galway and 
Belclare mutations in Cambridge and Belclare ewes [51] and more recently the 
Lacaune mutation identified in the Lacaune sheep breed [52]. All mutations 
found so far in the BMP-15 gene are associated with an increased ovulation 
rate and sterility in heterozygous and homozygous ewes, respectively [5, 51, 
52]. Ewes heterozygous simultaneously for both Belclare and Galway or 
Inverdale and Hanna mutations were also infertile showing a phenotype similar 
to the observed in homozygous ewes for each mutation [50, 51]. Recently, the 
Galway mutation was also found in the Small Tailed Han breed with 
heterozygous mutant ewes producing 0.55 more lambs than the wild-type [53].  
 The High Fertility mutation (Table 2) was identified in the mature domain 
of another oocyte secreted cytokine, GDF-9. Similar to the BMP-15 mutations 
it increases ovulation rate in heterozygous ewes while arresting 
folliculogenesis at primary stage in homozygous females [51]. 
Table 2. Major genes affecting ovulation rate in sheep and in which the causing 
mutation has been identified. 
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Mutation Gene Base Aminoacid Location 
Galway BMP-15 C718T Gln239STOP Prepeptide 
Hanna BMP-15 C871T Glu291STOP Mature peptide 
Inverdale BMP-15 T896A Val299Asp Mature peptide 
Lacaune BMP-15 G963A Cys321Tyr Mature peptide 
Belclare BMP-15 C1100T Ser367Ile Mature peptide 
High Fertility GDF-9 C1184T Ser395Phe Mature peptide 
Booroola BMPR1B A746G Gln249Arg Intracellular 
domain 
 
 The Booroola mutation is the only one so far identified in a receptor 
instead of a BMP ligand (Table 2). It is caused by a single point mutation in 
the BMP receptor type IB, which is located in the subdomain 3 of the receptor 
kinase domain [6-8]. It has an additive effect on ovulation with wild type 
females (++) presenting 1-2 ovulations, heterozygous (B+) showing three or 
four ovulations and homozygous (BB) ewes having five or more ovulations per 
cycle [54]. The Booroola mutation was initially described in flocks with a 
Merino origin, but since then has been found in the Garole, Javanese, Hu and 
Han sheep breeds [55, 56].  
 Ewes carrying both the Inverdale and the Booroola mutations had an 
ovulation rate that was greater than expected for an additive effect alone [57]. 
Small Tailed Han ewes carrying mutations in both BMPRIB and BMP-15 
genes (Booroola and Galway) also had greater litter size than those with either 
mutation alone [53].  The BMP-15 signalling pathway [58] through BMPRII 
and BMPRIB activating smad 1/5/8 phosphorylation can offer support to these 
observations.  
 Ewes bearing one mutant allele of the BMP-15 gene (Galway or Belclare 
mutations) and a mutant allele of the GDF-9 gene (High Fertility mutation) 
have an additive effect on the ovulation rate supporting the view that GDF-9 
and BMP-15 have distinct biological effects [51]. This view is also supported 
by evidence derived from immunization studies, which demonstrated that 
BMP-15 and GDF-9 are both essential for normal follicular development and 
control of ovulation rate [59]. 
 The mechanism of action of the mutations affecting ovulation rate in sheep 
are not fully elucidated but nevertheless several hypothesis have been put 
forward. However the characteristic that is consistent among these animals is 
that prolific sheep ovulate more follicles, which mature at smaller diameter 
producing a similar endocrine milieu [60, 61]. It is likely that the major effect 
of the mutated gene is evident in the ovary. This local effect has been 
demonstrated in ewes Booroola rendered hypogonadotrofic by GnRH 
antagonist and infused with a standard gonadotrophin regime, which 
maintained the difference in ovulation rate characteristic of each genotype 
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[62]. This increased ovulation rate in sheep carrying Booroola mutation is 
related to a reduced rate of atresia, since animals of an old age carrying or not 
the mutation show no differences on the estimated remaining follicular pool 
[63]. 
 The cause of increased ovulation in the ewes carrying mutations in the 
BMP-15 gene could be explained by a simple reduction in the protein 
production, since the Hanna and Galway mutation induce a premature stop 
codon leading to a truncation in the protein [5, 51].  In vitro protein expression 
systems show that the BMP-15 with the Inverdale mutation can form non-
covalent dimers but the processing efficiency of BMP-15 mutant proprotein is 
significantly lower than wild-type BMP-15. When GDF-9 is co-expressed, the 
processing and secretion of mutant BMP-15 is abolished, and the processing of 
GDF-9 is also marked reduced, suggesting that the heterodimers of mutant 
BMP-15/GDF-9 proproteins are not susceptible to proteolytic cleavage [13].  
Expanding the use of expression systems to BMP-15 with the Belclare or 
Inverdale mutations and GDF-9 with the High Fertility mutation showed that 
when individually expressed, both BMP-15 mutations did not disturb the 
processing, secretion, and dimerization of the mature proteins or had any effect 
on the biological activity of the molecules. However, when mutant BMP-15 is 
co-expressed with wild-type GDF-9, the secretion of mutant BMP-15 and 
GDF-9 is marked reduced. The expression of mutant GDF-9 with wild-type 
BMP-15 has no effect on BMP-15 and mutant GDF-9 secretion. In addition, 
when mutant GDF-9 is co-expressed with mutant BMP-15, the secretion levels 
of both proteins were significantly lower than those of cells co-expressing wild 
type GDF-9 and mutant BMP-15 [64]. Protein expression in vitro of BMP-15 
with the Lacaune mutation resulted in an impairment of the maturation process 
of the BMP15 protein, resulting in a defective secretion of both the precursor 
and mature peptide, which was not due to any alteration in the BMP-15 
transcription levels [52].  Interestingly, the main effect of the mutations seems 
to be at post-transcriptional level because mRNA abundance of BMP-15 or 
GDF-9 are also not altered by the Inverdale Mutation [5, 65]. Since BMP-15 
and GDF-9 are both product of the oocyte in sheep, and expressed in a very 
similar pattern, the common mechanism among all mutations would be a 
reduction on the processing and hence biologically active ligands. 
 The hypothesis of increased ovulation rate in animals with reduced 
biologically available BMP-15 and GDF-9 is supported by studies in rodents 
that indicate that BMP-15 reduced the expression of FSH receptor mRNA in 
granulosa cells and consequently the levels of FSH induced expression of 
mRNAs encoding the steroidogenic enzymes StAR, P450scc, P450 aromatase 
and 3beta-HSD. There was also a reduction in the expression of LH receptor, 
and inhibin/activin subunits [66]. Granulosa cells cultured with GDF-9 reduce 
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FSH-stimulated progesterone and oestradiol production and also In FSH-induced 
LH receptor expression. This inhibitory on granulosa cell differentiation were 
accompanied by decreases in the FSH-induced cAMP production [67]. 
However, in rodents both GDF-9 and BMP-15 induce marked increase in 
granulosa cells numbers in vitro [12] while in sheep they have no effect on 
granulosa proliferation [24]. 
 In vitro, ovarian granulosa cells from BB ewes are less responsive than 
granulosa cells ++ ewes to the inhibitory effect of BMP-4 on progesterone 
secretion in vitro [6]. The presence of the Booroola mutation is associated with 
a decreased responsiveness of granulosa cells to the action of BMP-4 but not 
TGFbeta-1 and activin-A, which show similar inhibitory effects on progesterone 
secretion by granulosa cells disregarding the genotype. Transfection experiments 
with co-expression of Booroola mutant BMPR1-B and BMPR2 failed show 
activation of BMPRIB by BMP-4, suggesting that the mutant receptor is 
associated with a reduction in signalling activity [37]. 
 A recent study that compared the behaviour of granulosa and theca cells 
from BB and ++ ewes in vitro. Showed that when exposed to the same 
gonadotrophin environment granulosa cells from mutant ewes produce more 
oestradiol and inhibin-a with the similar action being observed in the 
androstenedione secretion by theca cells. Cells from mutant ewes are also more 
sensitive to the action of BMP-2, -4, and -6 with the granulosa cells producing 
more oestradiol and inhibin and theca cells higher androstenedione secretion 
when treated with same concentration of BMP. These results provide evidence to 
support the hypothesis that the Booroola mutation increases the BMP response 
of somatic cells when stimulated to differentiate by gonadotrophin [32]. 
 Taking in account these observations, we propose that the Booroola 
mutation could act on a novel pathway involving BMPs that inhibits granulosa 
cell differentiation. This inhibitory pathway involves the BMPR1B and in the 
wild type normally acts to prevent the development of more than one or two 
ovulatory follicles. The mutated form of the receptor is partially disabled in the 
Booroola [37] and hence fewer developing follicles become atretic and more are 
available at the point of selection of the ovulatory follicles. Alternatively the 
mutant form of the receptor could be stimulatory since the cells from mutant 
animals show earlier differentiation in vitro even without addition of exogenous 
BMPs [32]. Further experiments investigating the relevant components of the 
BMP pathways in the ovary should help clarify the mechanisms involved in the 
increase in ovulation rate in high fecundity breeds of sheep. 
Conclusions 
 The expression pattern of BMPs in the mammalian ovary with ligands in 
the oocyte, granulosa and theca cells, along with the widespread distribution of 
their receptors and antagonists, give the opportunity for the establishment of 
BMPs in folliculogenesis 39 
several levels of local regulation of folliculogenesis and ovulation rate. The 
BMPs are implicated in the regulation of several key points of ovarian and 
follicle development spreading from the very beginning during the formation 
of the foetal ovary, regulation of primordial follicles entry into the growing 
pool, granulosa and theca cell function and finally affecting the number of 
follicles capable of ovulating. The mammalian domestic species can offer an 
excellent counterpoint to the rodent models used to investigate 
folliculogenesis. The sheep naturally occurring mutations in BMP ligands and 
receptor are of particular interest and have shed some light on very 
fundamental steps of folliculogenesis and on the regulation of ovulation rate. 
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